Shield's Feraccru likely to command 'high market share and branded pricing'
Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru.
The drug's approved and marketed in Europe, with a US approval decision pending for July 27.
Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.
